Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Furmonertinib +/- Bevacizumab in EGFR+ Lung Adenocarcinoma
NCT05503667Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in lung adenocarcinoma, sponsored by Shanghai Pulmonary Hospital. Started Feb 2022; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05503667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05503667.